Hansoh Pharmaceutical Group Company Limited (simplified Chinese: 翰森制药集团有限公司; traditional Chinese: 翰森製藥集團有限公司; pinyin: Hànsēn Zhìyào Jítuán Yǒuxiàn Gōngsī) is a pharmaceutical company that manufactures and sells various types of medicine in mainland China.[1] It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair.[2] Zhong and her family own 66% of the company.[3] It is the largest psychotropic drug producer in China.[4]
Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange (SEHK: 3692) on 14 June 2019.[5][6][7][8]
In August 2022, it was announced that the company's stock would be added to the Hang Seng Index.[9]
See also
editReferences
edit- ^ "翰森製藥集團有限公司簡介". Archived from the original on 2020-09-26. Retrieved 2020-03-29.
- ^ "翰森製藥集團有限公司發展歷程". Archived from the original on 2020-07-29. Retrieved 2020-03-29.
- ^ "Hang Seng review shines light on China's 6th richest woman at Hansoh Pharma". South China Morning Post. 22 August 2022. Retrieved 6 January 2023.
- ^ "Chem teacher behind pharmaceutical firm to be China's third-richest woman". South China Morning Post. 13 June 2019. Retrieved 6 January 2023.
- ^ "翰森製藥入場費逾2.88萬元". 2019-05-30. Archived from the original on 2020-03-29.
- ^ "翰森製藥超購11倍". 信報. 2019-06-13. Archived from the original on 2020-03-29.
- ^ "翰森製藥集團有限公司招股公告" (PDF). Archived from the original (PDF) on 2020-03-29. Retrieved 2020-03-29.
- ^ "翰森製藥集團有限公司招股資料" (PDF). Archived from the original (PDF) on 2020-11-26. Retrieved 2020-03-29.
- ^ "Baidu, Shenhua Energy to join Hang Seng Index as members rise to 73 stocks". South China Morning Post. 19 August 2022. Retrieved 6 January 2023.